Solid Biosciences Q2 2021 Earnings Report
Key Takeaways
Solid Biosciences reported collaboration revenue of $3.6 million for the second quarter of 2021, driven by their collaboration agreement with Ultragenyx. The company's research and development expenses increased to $15.5 million, and they ended the quarter with approximately $249 million in cash and investments.
Advanced clinical activities to prepare for the next patient to be dosed in the IGNITE DMD clinical trial of SGT-001, with next patient dosing anticipated in Q4 2021.
Progressed the next generation Duchenne gene therapy program, SGT-003.
Advanced the Duchenne collaboration with Ultragenyx.
Ended Q2 with approximately $249 million in cash and investments, providing a cash runway into Q4 2022.
Solid Biosciences
Solid Biosciences
Solid Biosciences Revenue by Segment
Forward Guidance
The company expects that its cash, cash equivalents and available-for-sale securities will enable Solid to invest in its Duchenne gene therapy programs and capital expenditures into the fourth quarter of 2022.